""""""""Mucopolysaccharidosis I (MPS I) is an inherited lysosomal storage disease due to deficiency of alpha-Liduronidase. Recombinant human alpha-L-iduronidase (rhIDU) is available as laronidase (trade name """"""""Aldurazyme"""""""") for intravenous delivery to treat physical disease due to MPS I. While partially effective for physical disease, intravenous rhIDU does not treat neurological symptoms of MPS I, because the blood-brain barrier prevents the bulk of the administered protein from entering the central nervous system (CNS). Patients with MPS I suffer from progressive neurological disease, including cognitive decline and dementia, as well as spinal cord compression, hearing and vision problems, hydrocephalus and headaches. Our preclinical research has found that intrathecal (IT) administration of rhIDU can disperse throughout the neuraxis, reach deep brain structures and remove brain lysosomal storage in MPS I dogs. We have treated a small number of MPS I subjects with IT rhIDU for disease-related spinal cord compression and have found no significant safety concerns for this approach. Currently, we are conducting a 2-year randomized study of IT rhIDU for cognitive decline in MPS I patients, which was funded as a pilot project by the LDN (NCT008523580). This new project would permit a five-year extension study for participants in the pilot project, which would allow us to collect long-term data on safety and efficacy. The primary safety outcome measure will be the rate and severity of treatment-related adverse effects. The primary efficacy outcome measure will be the mean intra-subject change in memory score between baseline and the subject's final visit. Other important efficacy measures are changes in scores of tests of other neuropsychological domains and changes in 3 Tesla brain magnetic resonance imaging (MRI) parameters, such as volumes, morphology, diffusion abnormalities and white matter fiber tracking. Currently, there are no treatment options for the brain in MPS I patients, except for the youngest, most severely affected patients, who may be considered for hematopoietic stem cell transplantation. If successful, intrathecal rhIDU would bring major innovation to the clinical care of MPS I patients.

Public Health Relevance

Our study will investigate if injecting recombinant human alpha-L-iduronidase, the enzyme missing in patients with mucopolysaccharidosis type I, into the spinal fluid of these patients, will treat symptoms of cognitive decline such as memory loss, language and learning difficulties. This will be the first long-term study of this treatment approach in this disease and will demonstrate if this approach is safe and effective.

National Institute of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZTR1-CI-8 (01))
Program Officer
Morris, Jill A
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Minnesota Twin Cities
United States
Zip Code
Ou, Li; Przybilla, Michael J; Whitley, Chester B (2018) Metabolomics profiling reveals profound metabolic impairments in mice and patients with Sandhoff disease. Mol Genet Metab :
McIntosh, Paul T; Hobson-Webb, Lisa D; Kazi, Zoheb B et al. (2018) Neuroimaging findings in infantile Pompe patients treated with enzyme replacement therapy. Mol Genet Metab 123:85-91
Nestrasil, Igor; Ahmed, Alia; Utz, Josephine M et al. (2018) Distinct progression patterns of brain disease in infantile and juvenile gangliosidoses: Volumetric quantitative MRI study. Mol Genet Metab 123:97-104
Ou, Li; Przybilla, Michael J; Koniar, Brenda et al. (2018) RTB lectin-mediated delivery of lysosomal ?-l-iduronidase mitigates disease manifestations systemically including the central nervous system. Mol Genet Metab 123:105-111
Desai, Ankit K; Walters, Crista K; Cope, Heidi L et al. (2018) Enzyme replacement therapy with alglucosidase alfa in Pompe disease: Clinical experience with rate escalation. Mol Genet Metab 123:92-96
Sindelar, Miriam; Dyke, Jonathan P; Deeb, Ruba S et al. (2018) Untargeted Metabolite Profiling of Cerebrospinal Fluid Uncovers Biomarkers for Severity of Late Infantile Neuronal Ceroid Lipofuscinosis (CLN2, Batten Disease). Sci Rep 8:15229
Shapiro, Elsa G; Whitley, Chester B; Eisengart, Julie B (2018) Beneath the floor: re-analysis of neurodevelopmental outcomes in untreated Hurler syndrome. Orphanet J Rare Dis 13:76
Ou, L; Przybilla, M J; Whitley, C B (2018) SAAMP 2.0: An algorithm to predict genotype-phenotype correlation of lysosomal storage diseases. Clin Genet 93:1008-1014
Eisengart, Julie B; Rudser, Kyle D; Xue, Yong et al. (2018) Long-term outcomes of systemic therapies for Hurler syndrome: an international multicenter comparison. Genet Med 20:1423-1429
Kazi, Zoheb B; Desai, Ankit K; Troxler, R Bradley et al. (2018) An immune tolerance approach using transient low-dose methotrexate in the ERT-naïve setting of patients treated with a therapeutic protein: experience in infantile-onset Pompe disease. Genet Med :

Showing the most recent 10 out of 118 publications